Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Cetuximab, Bevacizumab Equivalent as First-Line Therapy in KRAS Wild-Type mCRC

June 28th 2014

A head-to-head comparison of cetuximab and bevacizumab in a phase III trial that was nearly 10 years in the making showed equivalence for chemotherapy plus either agent in terms of OS, PFS, and response rates for patients with certain previously untreated metastatic colorectal cancers.

Palliative Resection Associated With Improved Survival in mCRC

June 28th 2014

Initial treatment with surgical resection of the primary tumor followed by systemic treatment yielded a 4.7-month OS benefit compared with the same treatments administered in the reverse order in patients with mCRC receiving palliative care.

Dr. Bendell Discusses a Phase III Study of Apatinib in Gastric Cancer

June 28th 2014

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses a randomized phase III placebo-controlled trial that explored apatinib as a treatment for patients with advanced gastric cancer.

Dr. Venook Discusses Implications of the 80405 Study

June 28th 2014

Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial on the targeted therapies administered in colorectal cancer.

TAS-102 Monotherapy Improves OS, PFS in Refractory mCRC

June 28th 2014

Treatment with the oral nucleoside TAS-102 significantly extended OS and PFS for patients with metastatic colorectal cancer refractory to standard therapies.

Dr. Wang-Gillam Discusses the NAPOLI-1 Trial in Pancreatic Cancer

June 28th 2014

Andrea Wang-Gillam, MD, PhD, from the Siteman Cancer Center, discusses the trial design and results of the phase III NAPOLI-1 trial that examined MM-398 with 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer following progression on gemcitabine-based therapy.

Active Maintenance Improves PFS in mCRC

June 28th 2014

Two active maintenance regimens following disease stabilization with standard induction therapy demonstrated superior disease-free outcomes compared with no treatment in patients with metastatic colorectal cancer.

Ramucirumab Benefit for US Patients With Gastric Cancer Mirrors Global Results

June 27th 2014

A geographic analysis of clinical trial results supporting the use of ramucirumab in advanced gastric cancer demonstrated that patients in the United States and other Western nations experienced similar survival gains and adverse events as did their counterparts in two other regions of the world.

Regorafenib Offers Effective Option for Asian Patients With mCRC

June 27th 2014

Treatment with regorafenib significantly improved OS and PFS in an Asian population of patients with previously treated mCRC.

MM-398 Improves OS, PFS in Phase III Pancreatic Cancer Study

June 27th 2014

Second-line treatment with MM-398 plus 5-FU and leucovorin extended OS, PFS, and ORR compared with 5-FU and leucovorin alone for patients with metastatic pancreatic cancer.

Dr. Peeters on the Frequency of S492R Mutations Following EGFR Inhibition in mCRC

June 27th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.

Dr. Tabernero on Sequencing Angiogenesis Inhibitors in mCRC

June 27th 2014

Josep Tabernero, MD, PhD, head, Medical Oncology Department, Vall d'Hebron University Hospital, director, Vall d'Hebron Institute of Oncology, discusses his opinions on which patients with metastatic colorectal cancer should receive aflibercept following bevacizumab.

Ruxolitinib Combo Improves Outcomes in Metastatic Pancreatic Cancer

June 26th 2014

Adding ruxolitinib to capecitabine as a second-line treatment for patients with metastatic pancreatic cancer significantly improved survival for a subgroup with a high degree of local and systemic inflammation compared with capecitabine plus placebo.

Adding Cetuximab to Chemoradiation in Non-operable Esophageal Cancer Does Not Improve Survival

June 26th 2014

Adding cetuximab to concurrent chemoradiotherapy did not improve overall survival in patients with adenocarcinoma or squamous cell carcinoma of the esophagus

Prognostic Scale Developed for Overall Survival in Locally Advanced Pancreatic Cancer

June 26th 2014

Four independent prognostic factors for improved overall survival in patients with locally advanced pancreatic cancer emerged from an analysis of the LAP 07 phase III trial.

Dr. O'Reilly on Nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX in Pancreatic Cancer

June 25th 2014

Eileen M. O'Reilly, MD, associate director, David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discusses using nab-paclitaxel plus gemcitabine versus FOLFIRINOX as treatment for patients with untreated metastatic pancreatic cancer.

Dr. Tempero Discusses Hereditary Pancreatic Cancer

June 25th 2014

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the two main types of hereditary pancreatic cancer.

Dr. Renschler Discusses Updated Results of the MPACT Study

June 20th 2014

Markus Renschler, MD, vice president, global head, Hematology Oncology Medical Affairs at Celgene, discusses updated results of the MPACT study, which examined nab-paclitaxel plus gemcitabine vs gemcitabine for patients with metastatic pancreatic cancer.

Nab-Paclitaxel Compares Favorably in Pancreatic Cost-Effectiveness Study

June 17th 2014

A regimen of nab-paclitaxel (Abraxane) and gemcitabine is a cost-effective option for the first-line treatment of patients with metastatic pancreatic cancer because it delivers a survival advantage at a price comparable to the cost of an existing combination therapy

RAS Mutations Ready for Prime Time in mCRC

June 12th 2014

A multitude of studies presented over the course of the past year have emphasized the importance of broader RAS mutational analyses outside of traditional KRAS testing for patients with metastatic colorectal cancer.